The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment
Open accessAbstract
The tumor microenvironment consists of tumor, immune, stromal, and inflammatory cells which produce cytokines, growth factors, and adhesion molecules that promote tumor progression and metastasis. Of particular interest in this setting is interleukin-1 (IL-1), a pleiotropic cytokine with numerous roles in both physiological and pathological states. It is known to be up regulated in many tumor types and has been implicated as a factor in tumor progression via the expression of metastatic and angiogenic genes and growth factors. A number of studies have reported that high IL-1 concentrations within the tumor microenvironment are associated with a more virulent tumor phenotype. Solid tumors in which IL-1 has been shown to be up regulated include breast, colon, lung, head and neck cancers, and melanomas, and patients with IL-1 producing tumors have generally bad prognoses. The exact mechanisms by which IL-1 promotes tumor growth remain unclear, though the protein is believed to act via induction of pro-metastatic genes such as matrix metalloproteinases and through the stimulation of adjacent cells to produce angiogenic proteins and growth factors such as VEGF, IL-8, IL-6, TNFα, and TGFβ. The IL-1 receptor antagonist (IL-1ra) is a naturally occurring inhibitor to IL-1 and acts by binding to the IL-1 receptor without activating it. The protein has been shown to decrease tumor growth, angiogenesis, and metastases in murine xenograft models. Our focus in this review is to summarize the known data on the role of IL-1 in tumor progression and metastasis and the use of IL-1 inhibition as a novel therapeutic approach in the treatment of solid organ malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Biologic basis for interleukin-1 in disease.
Dinarello, C. (1996) · Blood · doi:10.1182/blood.v87.6.2095.bloodjournal8762095 · Cited by 4,344
Interleukin-1 and interleukin-1 antagonism
Dinarello, C. (1991) · Blood · doi:10.1182/blood.v77.8.1627.1627 · Cited by 2,304
Altered Cytokine Export and Apoptosis in Mice Deficient in Interleukin-1β Converting Enzyme
Kuida, K., Lippke, J. A., Ku, G., Harding, M. W., Livingston, D. J., Su, M. S.-S., & Flavell, R. A. (1995) · Science · doi:10.1126/science.7535475 · Cited by 1,616
Li, P., Allen, H., Banerjee, S., Franklin, S., Herzog, L., Johnston, C., McDowell, J., Paskind, M., Rodman, L., Salfeld, J., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90490-5 · Cited by 1,417
IL-1 is required for tumor invasiveness and angiogenesis
Voronov, E., Shouval, D. S., Krelin, Y., Cagnano, E., Benharroch, D., Iwakura, Y., Dinarello, C. A., & Apte, R. N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437939100 · Cited by 1,023
The Role of Interleukin-1 in Disease
Epstein, F. H., Dinarello, C. A., & Wolff, S. M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301143280207 · Cited by 954
Interleukin-1 receptor antagonist reduces mortality from endotoxin shock
Ohlsson, K., Björk, P., Bergenfeldt, M., Hageman, R., & Thompson, R. C. (1990) · Nature · doi:10.1038/348550a0 · Cited by 853
Infections as a major preventable cause of human cancer
Kuper, H., Adami, H. ‐., & Trichopoulos, D. (2000) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2000.00742.x · Cited by 740
Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer.
Chen, Z., Malhotra, P. S., Thomas, G. R., Ondrey, F. G., Duffey, D. C., Smith, C. W., Enamorado, I. I., Yeh, N. T., Kroog, G. S., Rudy, S., et al. (1999) · PubMed · Cited by 486
Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines
Mantovani, A., Locati, M., Vecchi, A., Sozzani, S., & Allavena, P. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)01941-x · Cited by 383
Cytokine traps: multi-component, high-affinity blockers of cytokine action
Economides, A. N., Carpenter, L. R., Rudge, J. S., Wong, V., Koehler-Stec, E. M., Hartnett, C., Pyles, E. A., Xu, X., Daly, T. J., Young, M. R., et al. (2003) · Nature Medicine · doi:10.1038/nm811 · Cited by 359
Cominelli, F., Nast, C. C., Clark, B. D., Schindler, R., Lierena, R., Eysselein, V. E., Thompson, R. C., & Dinarello, C. A. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114799 · Cited by 333
The role of interleukin 1 in growth and metastasis of human cancer xenografts.
Elaraj, D. M., Weinreich, D. M., Varghese, S., Puhlmann, M., Hewitt, S. M., Carroll, N. M., Feldman, E. D., Turner, E. M., & Alexander, H. R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1603 · Cited by 288
Self-citationIL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways
Schraufstatter, I. U., Chung, J., & Burger, M. (2001) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.2001.280.6.l1094 · Cited by 278
Saijo, Y., Tanaka, M., Miki, M., Usui, K., Suzuki, T., Maemondo, M., Hong, X., Tazawa, R., Kikuchi, T., Matsushima, K., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.469 · Cited by 249
Symons, J. A., Young, P. R., & Duff, G. W. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1714 · Cited by 227
Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention
Braddock, M., & Quinn, A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1342 · Cited by 214
Rudolphi, K., Gerwin, N., Verzijl, N., van der Kraan, P., & van den Berg, W. (2003) · Osteoarthritis and Cartilage · doi:10.1016/s1063-4584(03)00153-5 · Cited by 213
Interleukin-1—a major pleiotropic cytokine in tumor–host interactions
Apte, R. N., & Voronov, E. (2002) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00014-7 · Cited by 212
Apte, R. N., Krelin, Y., Song, X., Dotan, S., Recih, E., Elkabets, M., Carmi, Y., Dvorkin, T., White, R. M., Gayvoronsky, L., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.010 · Cited by 211
Barillé, S., Akhoundi, C., Collette, M., Mellerin, M.-P., Rapp, M.-J., Harousseau, J.-L., Bataille, R., & Amiot, M. (1997) · Blood · doi:10.1182/blood.v90.4.1649 · Cited by 183
Smith, D. E., Hanna, R., Friend, D., Moore, H., Chen, H., Farese, A. M., MacVittie, T. J., Virca, G. D., & Sims, J. E. (2003) · Immunity · doi:10.1016/s1074-7613(02)00514-9 · Cited by 182
IL-1 Receptor Accessory Protein Is an Essential Component of the IL-1 Receptor
Cullinan, E. B., Kwee, L., Nunes, P., Shuster, D. J., Ju, G., McIntyre, K. W., Chizzonite, R. A., & Labow, M. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.10.5614 · Cited by 172
Endres, S., Cannon, J. G., Ghorbani, R., Dempsey, R. A., Sisson, S. D., Lonnemann, G., Meer, J. W. M. V. D., Wolff, S. M., & Dinarello, C. A. (1989) · European Journal of Immunology · doi:10.1002/eji.1830191222 · Cited by 169
Tumor necrosis factor acts as a tumor promoter in BALB/3T3 cell transformation.
Komori, A., Yatsunami, J., Suganuma, M., Okabe, S., Abe, S., Sakai, A., Sasaki, K., & Fujiki, H. (1993) · PubMed · Cited by 162
Burger, D., Chicheportiche, R., Giri, J. G., & Dayer, J. M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118045 · Cited by 159
Naik, S. M., Cannon, G., Burbach, G. J., Parker, S. R. S., Swerlick, R. A., Ansel, J. C., Caughman, S. W., & Wilcox, J. N. (1999) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1999.00750.x · Cited by 157
A CYTOKINE PROFILE OF NORMAL AND MALIGNANT OVARY
Burke, F., Relf, M., Negus, R. P. M., et al. (1996) · Cytokine · doi:10.1006/cyto.1996.0077 · Cited by 142
Rambaldi, A., Torcia, M., Bettoni, S., Vannier, E., Barbui, T., Shaw, A., Dinarello, C., & Cozzolino, F. (1991) · Blood · doi:10.1182/blood.v78.12.3248.3248 · Cited by 129
Re, F., Sironi, M., Muzio, M., Matteucci, C., Introna, M., Orlando, S., Pentón‐Rol, G., Dower, S., Sims, J. E., Colotta, F., et al. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.4.1841 · Cited by 102
Gemma, A., Takenaka, K., Hosoya, Y., Matuda, K., Seike, M., Kurimoto, F., Ono, Y., Uematsu, K., Takeda, Y., Hibino, S., et al. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00154-x · Cited by 90
ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs
Randle, J. C. R., Harding, M. W., Ku, G., Schönharting, M., & Kurrle, R. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.7.1207 · Cited by 90
Regulation of vascular endothelial growth factor expression in human colon cancer by interleukin-1β
Akagi, Y., Liu, W., Xie, K., Zebrowski, B. K., Shaheen, R. M., & Ellis, L. M. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690553 · Cited by 88
Nozaki, S., Sledge, G. W., & Nakshatri, H. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3241 · Cited by 77
Cytokine gene expression in human multiple myeloma
Portier, M., Zhang, X., Ursule, E., Lees, D. M., Jourdan, M., Bataille, R., & Klein, B. (1993) · British Journal of Haematology · doi:10.1111/j.1365-2141.1993.tb03341.x · Cited by 75
Jouvenne, P., Vannier, E. G., Dinarello, C. A., & Miossec, P. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199806)41:6<1083::aid-art15>3.0.co;2-9 · Cited by 74
Neidhart, M., Gay, R. E., & Gay, S. (2000) · Arthritis & Rheumatism · Cited by 69
Konishi, N., Miki, C., Yoshida, T., Tanaka, K., Toiyama, Y., & Kusunoki, M. (2005) · Oncology · doi:10.1159/000086768 · Cited by 60
Macrophage Control of Inflammation: Negative Pathways of Regulation of Inflammatory Cytokines
Mantovani, A., Muzio, M., Garlanda, C., Sozzani, S., & Allavena, P. (2000) · Novartis Foundation symposium · doi:10.1002/0470868678.ch8 · Cited by 53
A soluble binding protein specific for interleukin 1β is produced by activated mononuclear cells
Symons, J. A., Eastgate, J. A., & Duff, G. W. (1990) · Cytokine · doi:10.1016/1043-4666(90)90015-l · Cited by 53
Bossù, P., Visconti, U., Ruggiero, P., Macchia, G., Muda, M., Bertini, R., Bizzarri, C., Colagrande, A., Sabbatini, V., & Maurizi, G. (1995) · Europe PMC (PubMed Central) · Cited by 51
Weinreich, D. M., Elaraj, D. M., Puhlmann, M., Hewitt, S. M., Carroll, N. M., Feldman, E. D., Turner, E. M., Spiess, P. J., & Alexander, H. R. (2003) · PubMed · Cited by 48
Self-citationBischof, A. (2000) · doi:10.1002/1521-4141(200003)30:3
Cited by
A cytokine-mediated link between innate immunity, inflammation, and cancer
Lin, W.-W., & Karin, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31537 · Cited by 1,940
Ridker, P. M., MacFadyen, J. G., Thuren, T., Everett, B. M., Libby, P., Glynn, R. J., Ridker, P., Lorenzatti, A., Krum, H., Varigos, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32247-x · Cited by 1,344
Cytokines: From Clinical Significance to Quantification
Liu, C., Chu, D., Kalantar‐Zadeh, K., George, J., Young, H. A., & Liu, G. (2021) · Advanced Science · doi:10.1002/advs.202004433 · Cited by 940
Senescence-messaging secretome: SMS-ing cellular stress
Kuilman, T., & Peeper, D. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2560 · Cited by 909
Inflammation: Gearing the journey to cancer
KUNDU, J., & SURH, Y. (2008) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2008.03.002 · Cited by 803
Metadata
- Authors
- Lewis, A. M., Varghese, S., Xu, H., & Alexander, H. R.
- Venue
- Journal of Translational Medicine
- Published
- 2006-06
- Volume
- 4
- Issue
- 1
- Pages
- 48-48
- ISSN
- 1479-5876 (ISSN-L)
- OpenAlex
- W2140432305
- Cited by
- 443
- References
- 44
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.